Caribou Technologies

Caribou Biosciences is a clinical-stage biopharmaceutical company specializing in the development of next-generation allogeneic cell therapies using its proprietary CRISPR hybrid RNA-DNA (chRDNA) genome editing platform. Co-founded by Nobel laureate Jennifer Doudna, the company aims to improve the precision and efficiency of CRISPR editing to create "off-the-shelf" CAR-T and CAR-NK cell therapies with enhanced persistence and antitumor activity. Their lead clinical programs target hematologic malignancies such as B-cell non-Hodgkin lymphoma and multiple myeloma, with expanding research into solid tumors and autoimmune diseases. By utilizing sophisticated multiplex editing, Caribou seeks to overcome the limitations of first-generation cell therapies and provide transformative treatments for patients with devastating diseases.